GLP1R and fatty liver disease: Finally, dual GLP-1/glucagon agonists have been developed over the past years, showing a significant weight reduction, even bigger than the observed with the isolated use of GLP-1 and a more significant improvement of glycemia and fatty liver disease [138,139,140,141].